Form SC 13D/A MediWound Ltd. Filed by: Access Industries Holdings LLC


During the last five years, none of the Reporting Persons or to the knowledge of the Reporting Persons, any person listed on Annex A hereto, has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding has been or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.

Please see Annex A for information regarding the directors and executive officers of CBI.

Item 3.

Source and Amount of Funds or Other Consideration.

The disclosure in the seventh paragraph in Item 3 to the Schedule is hereby amended and restated as follows:

On June 29, 2020, Mr. Ofer Gonen and Mr. Assaf Segal, the then current Chief Executive Officer and the Chief Financial Officer of CBI, respectively, each in their capacity as a director of the Issuer, received options to acquire an aggregate of 200,000 Ordinary Shares under the Issuer’s 2014 Equity Incentive Plan, exercisable for $1.75 per share, which vest over three years beginning on June 29, 2020 and expires on June 29, 2025.

The disclosure in Item 3 to the Schedule is hereby supplemented by adding the following at the end thereof:

On June 15, 2021, Messrs. Gonen and Segal, each in their capacity as a director of the Issuer, received options to acquire an aggregate of 22,500 Ordinary Shares under the Issuer’s 2014 Equity Incentive Plan, exercisable for $5.36 per share, which vested on June 15, 2022 and expires on June 15, 2026.

On June 15, 2021, Messrs. Gonen and Segal, each in their capacity as a director of the Issuer, received restricted stock units exchangeable into 3,750 Ordinary Shares under the Issuer’s 2014 Equity Incentive Plan, which vested on June 15, 2022.

Pursuant to their employment agreements with CBI, Messrs. Gonen and Segal assigned their options and restricted stock units to CBI.

Item 4.

Purpose of Transaction.

The disclosure in Item 4 to the Schedule is hereby supplemented by adding the following at the end of it:

Mr. Gonen’s term as a member of the Issuer’s board of directors will end at the Issuer’s annual general meeting of shareholders scheduled for July 19, 2022, in connection with his appointment as Chief Executive Officer of the Issuer, effective June 30, 2022, and his resignation as Chief Executive Officer of CBI, effective June 30, 2022.

10

Leave a Comment